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4 structural proteins: spike, envelope, membrane, and nucleocapsid.
Spike = homotrimeric surface protein (favored target for antibodies/vaccines)
S1 = binds host cell receptor; S2 = fuses viral and host cell membranes
Complex genome with nine open reading frames and multiple mRNAs
Reducing viral titers is expected to have a profound impact on disease progression Wikipedia: SARS-CoV-2
SARS-CoV2
The RNAi Therapeutic Mechanism
Informational Drugs: Future of Medicine
4
Dianophore*
Ensemble of molecular 
features that determines 
PK/PD/ADME
Pharmacophore
Ensemble of molecular 
features that determines 
target recognition and 
modulation
Traditional, small molecule drug Informational drug
chemical structure
Dianophore
Ensemble of molecular 
features that determines 
PK/PD/ADME
Pharmacophore
Ensemble of molecular 
features that determines 
target recognition and 
modulation
Chemistry of the 
backbone and ligand
Sequence
*Dianophore—from the Greek “διανομή-dianomi” for distribution or delivery
Khvorova and Watts, 2016, Nature Biotech
RNAi Has Matured to Become A Defined Therapeutic Class




















Focus: minimal modification 
and LNP delivery













LNPs continue to 
show immune 
effects





Inclisiran® for Cholesterol Lowering Support 6-12 Month Efficacy with 
Single Injection




Reduce SARS CoV 2 or/and host factors in the lung as a 
treatment and prophylactic  of COVID19
THE IDEA
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Requirements for Development of siRNA-Based COVID19 Therapeutics
• Fully chemically-modified scaffolds supporting multi-month efficacy in vivo
• Chemical architectures supporting efficient lung delivery with acceptable safety profile
• LOCAL- Intratracheal
• Systemic
• Advanced bioinformatics to identify SARS-CoV2 regions of conservation
• Cocktail of three compounds is expected to be sufficient to minimized the risk of escape mutants 
development and full variants coverage
• Lead Compounds efficiently targeting SARS-CoV2


























Increasingly complex requirements for oligonucleotide chemistry
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Hassler, Turanov, Alterman et al, NAR, 2018, Haraszti, Roux, NAR, 2017
















1 mm1 m 25 mm
Hassler, Turanov , Alterman, et al, NAR 2018
Revusiran vs Inclisiran: Composition Defines Potency and Toxicity
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• No 5’ PS stabilization









• 5’ PS stabilization
• <1 gram a year/ 
patient
Etiology unresolved
Advanced Chemical Modification Scaffolds with Enhanced Stability
0 0.5 1 2 4 6 8 24 0 0.5 1 2 4 6 8 24
(mN)- PS(mN)-PS(mN)-PS (mN) (mN)- (xmN)- (xmN)-(xmN)
(Time in hour) (Time in hour)
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(Time in minutes)
(mN)- PO(mN)-PO(mN)-PO(mN)
Orders of magnitude increase in stability translates in higher tissue accumulation























1 0 0 0
















L i v e r K i d n e y s P l a c e n t a
* * * *
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In vivo siRNA Tissue Accumulation
A
üFully chemically-modified scaffolds supporting multi-month efficacy in vivo




• Advanced bioinformatics to identify SARS-CoV2 regions of conservation
• Cocktail of three compounds is expected to be sufficient to minimized the risk of escape mutants 
development and full variants coverage
• Lead Compounds efficiently targeting SARS-CoV2
• Experimental systems allowing study of SARS-CoV2 infection in living animals and cells
Requirements for Development of siRNA-Based COVID19 Therapeutics
Lung Delivery: Intratracheal vs Systemic
Local
• Non-invasive
• Support delivery to respiratory track 
(primary point of infection)
• May be affected by patient clinical stage
• Nebulization can increase infection 
spread
• Highly selective with minimal exposure to 
other tissues
Systemic
• Ease of clinical delivery
• Uniform lung distribution through 
capillary 
• No impact of patient clinical condition or 
lung inflammation









- Covalent / Cleavable
- Length / Hydrophobicity
- Degree of endosomal escape
siRNA structure/ Stability
PK Modifier
- Rate of kidney clearance
- AUC 
Path to Success: siRNA structure/stabilization, linker, PK modifier, 
Conjugate Identity
ü Improves circulation half-life and bioavailability
ü Allows siRNA penetration into a variety of tissues
ü Platform for exploring local and systemic delivery
Cholesterol-conjugated siRNA
Turanov et al., Nat Biotechnol., 2018
Yuan et al., Am J Physiol Renal Physiol., 2008
Khan et al., Mol. Ther. Nucleic Acids, 2016
Osborn and Khvorova, Nucleic Acid Ther., 2018
Soutscheck et al. Nature, 2004 
Lipid Conjugates Support Functional Delivery to Many Tissues
Important toxicity limiting its therapeutic use
ü Improves circulation half-life and bioavailability
ü Allows siRNA penetration into a variety of tissues
ü Platform for exploring local and systemic delivery
Cholesterol-conjugated siRNA
Turanov et al., Nat Biotechnol., 2018
Yuan et al., Am J Physiol Renal Physiol., 2008
Khan et al., Mol. Ther. Nucleic Acids, 2016
Osborn and Khvorova, Nucleic Acid Ther., 2018
Soutscheck et al. Nature, 2004 












































Biscans et al., Nucleic Acid Res., 2018
Biscans et al., J. Control. Release, 2019
Osborn et al., Nucleic Acid Res., 2018
Nikan et al., Bioconjug. Chem., 2017













































Biscans et al., Nucleic Acid Res., 2018
Biscans et al., J. Control. Release, 2019
Osborn et al., Nucleic Acid Res., 2018
Nikan et al., Bioconjug. Chem., 2017
Design of Lipid-siRNA Conjugates with Distinct Physicochemical 
Properties
Evaluation of Impact of Conjugate Chemistry on siRNA Delivery
SC, 20 mg/kg, n = 3, t = 48h. Leica DMi8 Microscope. 5x Tiled Arrays. DAPI (Blue), siRNA (Red). Scale = 1 mm
Biscans et al., Nucleic Acid Res., 2018




























































The Structure of the Conjugate Defines Liver/Kidney Distribution Ratio
Biscans et al., Nucleic Acid Res., 2018




























































Less hydrophobic High hydrophobic
Increased Hydrophobicity Correlates with Decreased Renal Clearance










































Osborn et al., Nucleic Acid Res., 2018
Wolfrum et al.Nat. Biotechnol., 2007 
Hydrophobicity Drives siRNA Partitioning into Distinct Lipoprotein 
Classes

































Intravenous injection, 20 mg/kg, t = 15 min, n = 2









Osborn et al., Nucleic Acid Res., 2018
Wolfrum et al.Nat. Biotechnol., 2007 
Hydrophobicity Drives siRNA Partitioning into Distinct Lipoprotein 
Classes
The chemical structure of the conjugate defines siRNA tissue distribution
SC, 20 mg/kg, t = 48 h, n=3.
Biscans et al., Nucleic Acid Res., 2018
Biscans et al., J. Control. Release, 2019 










































The Chemical Structure of The Conjugate Defines Tissue Accumulation  










































SC, 20 mg/kg, t = 48 h, n=3. Leica DMi8 Microscope. 5x Tiled Arrays. DAPI (Blue), siRNA (Red). Scale = 1 mm
Biscans et al., Nucleic Acid Res., 2018
Biscans et al., J. Control. Release, 2019 
Significant siRNA Delivery in Adrenal Glands












































































































DCA/PC-DCA Improves siRNA Extrahepatic Tissue Accumulation 
Compare to Cholesterol
Evaluation of Impact of Conjugate Chemistry on siRNA Delivery
Biscans et al., Nucleic Acid Res., 2018
Biscans et al., J. Control. Release, 2019 
Leica DMi8 Microscope. 40x magnification. DAPI (Blue), siRNA (Red). Scale = 50 μm (SC, 20 mg/kg, n =3, 48h)





siRNA Accumulation Leads to Functional Delivery in Multiple 
Extrahepatic Tissues
Lung Delivery: Intratracheal vs Systemic
Local
• Non-invasive
• Support delivery to respiratory track 
(primary point of infection)
• May be affected by patient clinical stage
• Nebulization can increase infection 
spread
• Highly selective with minimal exposure to 
other tissues
Systemic
• Ease of clinical delivery
• Uniform lung distribution through 
capillary 
• No impact of patient clinical condition or 
lung inflammation
• Significant exposure of other organs
The Chemical Scaffolds for Local and Systemic Delivery Are Different



























SYSTEMIC, SC; n=3, 48h, 5x, Scale=1 mm























































































































































Systemic vs Local Delivery to Lung: Differential Secondary Tissues 
Exposure Profiles
Intratracheal
Efficient Lung Delivery: Intratracheal and Systemic
Local
• Non-invasive
• Support delivery to respiratory track 
(primary point of infection)
• May be affected by patient clinical stage
• Nebulization can increase infection 
spread
• Highly selective with minimal exposure to 
other tissues
Systemic
• Ease of clinical delivery
• Uniform lung distribution through 
capillary 
• No impact of patient clinical condition or 
lung inflammation
• Significant exposure of other organs
Efficient Lung Delivery: Intratracheal and Systemic
Local
• Non-invasive
• Support delivery to respiratory track 
(primary point of infection)
• May be affected by patient clinical stage
• Nebulization can increase infection 
spread
• Highly selective with minimal exposure to 
other tissues
Systemic
• Ease of clinical delivery
• Uniform lung distribution through 
capillary 
• No impact of patient clinical condition or 
lung inflammation


























































üFully chemically-modified scaffolds supporting multi-month efficacy in vivo




• Advanced bioinformatics to identify SARS-CoV2 regions of conservation
• Cocktail of three compounds is expected to be sufficient to minimized the risk of escape mutants 
development and full variants coverage
• Lead Compounds efficiently targeting SARS-CoV2
• Experimental systems allowing study of SARS-CoV2 infection in living animals and cells
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Mod. siRNA with algorithmmod
Mod. siRNA with algorithmnon-mod
Non-mod. siRNA with algorithmnon-mod
Non-mod. siRNA with algorithmmod
A B
Development Algorithms for Modified siRNAs Design























<30% | >80% svm - RFE 50 <30% | >80% svm - RFE 120
SMV (Support Vector Machine – Kernel Adjustment)
Functional cutoff <30% Target Gene Expression
Recursive Feature Elimination (RFE)







0 5 10 15 20
1. Select features
2. Classify Functional/Nonfunctional sequences (cutoffs)
3. Develop an N-dimensional hyperplane that separates data






Use a hyperplane (line/multidimensional plane) to classify data
UMMS Nucleic Acid Chemistry Center: Only NFP
center in North America with gram-synthesis Capability
4 grams sFLT1_2283/2519/P2 
hsiRNAs formulated for 
baboon injections 



































siRNA Lead Compounds Against Key SARS-CoV2 Regions Identified
Targeting an RNA Virus: siRNA Cocktails
• RNA Viruses mutate
• Rate of SARS-CoV2 mutations is lower
• Use of cocktails (at least three 
compounds) minimizing escape 
mutants appearance
• Lead Cocktail:
• RTI-siCOVID: pp1ab, orf7, N 
üFully chemically-modified scaffolds supporting multi-month efficacy in vivo




üAdvanced bioinformatics to identify SARS-CoV2 regions of conservation
üCocktail of three compounds is expected to be sufficient to minimized the risk of escape mutants 
development and full variants coverage
üLead Compounds efficiently targeting SARS-CoV2
• Experimental systems allowing study of SARS-CoV2 infection in living animals and cells
Requirements for Development of siRNA-Based COVID19 Therapeutics
Drug Design Concepts for Anti-viral Therapies
• Target conservation regions
• Multiplexing, multiplexing, multiplexing
• Current lead compound: cocktail of three siRNAs 
• Highly similar PK/PD and ADME-tox properties makes siRNAs an ideal multiplexing  drug
• FDA allow defining a cocktail of several siRNAs as a single drug entity
• Target host factors involved in viral entry
Corum and Zimmer, March 
13, 2020. NYT.
Targeting Host Factors: SARS Infection Cycle- ACE2
Wrapp, et al., 2020. Science.
• S1-receptor binding stabilizes prefusion 
complex for cleavage of S2, which allows for 
the residues necessary for membrane fusion 
to be exposed
• SARS-CoV-2 does not produce the protease 




SARS: Membrane Fusion with Host Cell Requires Cleavage of S Protein
Furin cleaves SARS-CoV-2 spike Protein During Biosynthesis
• Four amino acid residue insertion at the S1/S2 
boundary compared to SARS-CoV S and SARSr-CoV S
• This results in the introduction of a furin cleavage site
Walls, A.C., et al. 2020. bioRxiv.
• SARS-CoV-2 is cleaved at S1/S2 site during 
biosynthesis in HEK293T, presumably by furin
• SARS-CoV-2 S is not cleaved at S1/S2 site 
before incorporation into virion
TMPRSS2 can Prime Spike Protein and Modulate SARS-CoV2 Entry
Hoffmann et al. 2020. Cell.
• E-64d is CatL inhibitor
• Camostat mesylate is a clinically proven TMPRSS2 inhibitor
• Vero don’t express TMPRSS2
• Vero made to express TMPRSS2 rescue SARS-CoV-2 entry from E-64d inhibition
Reduce SARS CoV 2 or/and host factors in the lung as a 
treatment and prophylactic  of COVID19
THE IDEA
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Impact of RTI-siCOVID on SARS-CoV2 Infection
• Cells
• VERO E6 –SARS-CoV2 infected cells (BCL3)
• SARS-CoV2 infected lung/air epithelia (BCL3)
• Animal models
• Mouse (ACE2), infected with SARS-CoV2(BCL3)
• Ferrets (BCL3)
• NHPs infected  with SARS-CoV2 (BCL4) Anthony Griffiths, Ph.D.
Rob Finberg, MD
üFully chemically-modified scaffolds supporting multi-month efficacy in vivo




üAdvanced bioinformatics to identify SARS-CoV2 regions of conservation
üCocktail of three compounds is expected to be sufficient to minimized the risk of escape mutants 
development and full variants coverage
üLead Compounds efficiently targeting SARS-CoV2
üExperimental systems allowing study of SARS-CoV2 infection in living animals and cells
Requirements for Development of siRNA-Based COVID19 Therapeutics
What we have
• Functional lung delivering platform systemic
• ~ 1% of injected dose accumulates in lungs (systemic)
• More than 2 month duration of effect following single sc injection
• Safe in NHPs with a single injection
• Functional lung delivery platform local (intratracheal)
• Significant lung accumulation (~ 20% )
• Minimized functional exposure to other tissues (essential for host gene targeting)
• Platform for identification of fully-chemically stabilized “clinical quality siRNAs”
• Advanced bioinformatics
• Synthetic capability to make up to 1000 oligonucleotides a week
• HTS screening platform
• Lead Compounds identified
• SARS-CoV2 targeting cocktails (IC50<20nM in passive uptake)
• FURIN, ACE2, TMPRSS2, IL6, IL6R  and other host factors form modulation of entry and inflammatory 
response
• Concept
• Target SARS CoV 2 genome in lungs as therapeutics and prophylaxis
• Target genes involved in SARS CoV 2 cellular transduction (ACE2, FURIN, TMPRSS2 etc) as a combinatorial therapeutics
Major Outstanding Questions and Concerns
• Would incomplete silencing of the virus be sufficient to have a clinically relevant 
outcome?
• Systemically, lung-delivering siRNAs distribute to many cell types, including monocytes. 
It is safe in healthy NHPs. Will additional immune cell exposure to siRNAs in the context 
of activating immune response would exaggerate the inflammatory response?
• What is the optimal time of treatment: prophylactic, early in disease, late in disease. 
How would you design a clinical trial in a context of active pandemic?
• What is an optimal route of administration?
• SC, IV, IT
Introduction to EAUs: Emergency Use Authorization
• FDA may issue an EAU if the following four conditions are met:
1. Serious or life-threatening disease or condition
2. Evidence of effectiveness (“May be effective” is enough for consideration for EUA)
3. Risk-Benefit analysis
• Evidences based on the following (but not limited to): results of domestic and foreign clinical trials, in vivo 
efficacy data from animal models, in vitro data. 
4. No alternatives or insufficient supply of approved alternatives
• Submission of an IND or IDE is not required for potential EAU products but human data 
from these studies may support the application for EAU
Source: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities
Accelerated Drug Development Pipeline in Times of Pandemics: 4-6 
Month from Viral Sequence to the First in Patient  Goal
February March April May June July
Leads Design
Assays development
Synthesis ( ~ 300 compounds)
Screening
Lead identification and validation
Lead Scale up
Supply chain
Lead GMP manufacturing (CMO)
Inimal model optimization
Lead validation in infected air/lung cultures (BCL3)






Animal model validation (efficacy and safety)
Regulatory
Month 1  Month2   Month3   Month4   Month5  Month6
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